Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - zydelig
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp702c9d84bc860bda988d99979df3de81
identifier: http://ema.europa.eu/identifier
/EU/1/14/938/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Zydelig 100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-702c9d84bc860bda988d99979df3de81
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/14/938/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - zydelig
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Zydelig is a cancer medicine that contains the active substance idelalisib. It works by blocking the effects of an enzyme involved in multiplication and survival of certain white blood cells called lymphocytes. Because this enzyme is overactivated in certain cancerous white blood cells, by blocking it, Zydelig will kill and reduce the number of cancer cells.
Zydelig may be used for the treatment of two different cancers in adults:
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is a cancer of a type of white blood cell called B-lymphocytes. In this disease, the lymphocytes multiply too quickly and live for too long, so that there are too many of them circulating in the blood.
In CLL Zydelig treatment is used in combination with another medicine (rituximab) in patients who have certain high-risk factors or in patients whose cancer has come back after at least one previous treatment.
Follicular lymphoma
Follicular lymphoma (FL) is a cancer of a type of white blood cell called B-lymphocytes. In follicular lymphoma, the B-lymphocytes multiply too quickly and live for too long, so there are too many of them in the lymph nodes. In FL Zydelig is used on its own in patients whose cancer has not responded to treatment with two previous cancer treatments.
Do not take Zydelig
Warnings and precautions
Talk to your doctor before taking Zydelig. Tell your doctor:
Serious and fatal infections have occurred in patients taking Zydelig. You should take additional medicine provided by your doctor while you are taking Zydelig to prevent one type of infection. Your doctor will monitor you for evidence of infection. Tell your doctor right away if you become ill (especially with a fever, cough or breathing difficulties) while you are taking Zydelig.
Tell your doctor immediately if you notice or someone notices in you: memory loss, trouble thinking, difficulty walking or sight loss these may be due to a very rare but serious brain infection which can be fatal (progressive multifocal leukoencephalopathy or PML).
You will need regular blood tests before and during treatment with Zydelig. This is to check that you do not have an infection, that your liver is working properly, and that your blood counts are normal. If necessary, your doctor may decide to stop treatment for a while, before starting treatment again at the same or a lower dose. Your doctor may also decide to permanently stop treatment with Zydelig.
Zydelig can cause severe diarrhoea. Tell your doctor right away at the first sign of diarrhoea.
Zydelig can cause lung inflammation. Tell your doctor right away:
Severe skin blistering conditions including Stevens-Johnson syndrome and toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in association with idelalisib treatment. Stop using idelalisib and seek medical attention immediately if you notice any of the symptoms described in section 4. Tell your doctor right away:
Laboratory tests may show an increase in white blood cells (called lymphocytes ) in your blood in the first few weeks of treatment. This is expected and may last for a few months. This generally does not mean that your blood cancer is getting worse. Your doctor will check your blood counts before or during treatment with Zydelig and in rare cases they may need to give you another medicine. Talk to your doctor about what your test results mean.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years of age because it has not been studied in this age group.
Other medicines and Zydelig
Zydelig should not be used with any other medicines unless your doctor has told you it is safe to do so.
Tell your doctor if you are taking, have recently taken or might take any other medicines. This is extremely important, as using more than one medicine at the same time can strengthen or weaken their effect.
Taking Zydelig with certain medicines may stop them working properly, or may make side effects worse. In particular, tell your doctor if you are taking any of the following:
Zydelig may be prescribed in combination with other medicines for the treatment of CLL. It is very important that you read the package leaflets that are provided with these medicines too.
Ask your doctor if you have any questions about any of your medicines.
Pregnancy and breast-feeding
You should not breast-feed while taking Zydelig. If you are currently breast-feeding, talk to your doctor before starting treatment. It is not known whether the active substance in Zydelig passes into human milk.
Driving and using machines
Zydelig is unlikely to affect your ability to drive or use machines.
Zydelig contains sunset yellow FCF (E110)
Tell your doctor if you have an allergy to sunset yellow FCF (E110). Zydelig contains sunset yellow FCF which may cause allergic reactions.
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
The recommended dose is 150 mg by mouth twice a day. However, your doctor may reduce this dose to 100 mg twice a day if you experience particular side effects.
Zydelig can be taken with or without food.
Swallow the tablet whole. Do not chew or crush the tablet. Tell your doctor if you have problems swallowing tablets.
If you take more Zydelig than you should
If you accidentally take more than the recommended dose of Zydelig, you may be at increased risk of side effects with this medicine (see section 4, Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep the bottle and this leaflet with you so that you can easily describe what you have taken.
If you forget to take Zydelig
Take care to not miss a dose of Zydelig. If you miss a dose by less than 6 hours, take the missed dose right away. Then take your next dose as usual. If you miss a dose by more than 6 hours, wait and take the next dose at your usual time.
Do not stop taking Zydelig
Do not stop taking this medicine unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects could be serious.
STOP taking Zydelig and seek medical help immediately if you experience any of the following:
Other side effects
Very common side effects (may affect more than 1 in 10 people)
Blood tests may also show:
Common side effects (may affect up to 1 in 10 people)
Blood tests may also show:
Reporting of side effects
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Zydelig contains
The active substance is idelalisib. Each film-coated tablet contains 100 mg of idelalisib.
The other ingredients are: Tablet core: Microcrystalline cellulose, hydroxypropyl cellulose (E463), croscarmellose sodium, sodium starch glycolate, magnesium stearate.
Film-coating: Polyvinyl alcohol (E1203), macrogol 3350 (E1521), titanium dioxide (E171), talc (E553B), sunset yellow FCF (E110) (see Section 2, What you need to know before you take Zydelig).
What Zydelig looks like and contents of the pack
The film-coated tablets are orange, oval-shaped tablets, debossed on one side with GSI and 100 on the other side.
The following pack size is available: outer carton containing 1 plastic bottle of 60 film-coated tablets.
Marketing Authorisation Holder Gilead Sciences Ireland UC Carrigtohill County Cork, T45 DPIreland
Manufacturer Gilead Sciences Ireland UC IDA Business & Technology Park Carrigtohill County Cork Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Gilead Sciences Belgium SRL-BV T l/Tel: + 32 (0) 24 01 35 Lietuva Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1
Gilead Sciences Ireland UC .: + 353 (0) 1 686 1Luxembourg/Luxemburg Gilead Sciences Belgium SRL-BV T l/Tel: + 32 (0) 24 01 35 esk republika Gilead Sciences s.r.o. Tel: + 420 910 871 Magyarorsz g Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Deutschland Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0
Nederland Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 Eesti Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Norge Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1
Gilead Sciences . . : + 30 210 8930 sterreich Gilead Sciences GesmbH Tel: + 43 1 260 Espa a Gilead Sciences, S.L. Tel: + 34 91 378 98 Polska Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8France Gilead Sciences T l: + 33 (0) 1 46 09 41 Portugal Gilead Sciences, Lda. Tel: + 351 21 7928Hrvatska Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Rom nia Gilead Sciences (GSR) S.R.L. Tel: + 40 31 631 18 Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 Slovenija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1 sland Gilead Sciences Sweden AB S mi: + 46 (0) 8 5057 1Slovensk republika Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 Italia Gilead Sciences S.r.l. Tel: + 39 02 439Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1
Gilead Sciences . . : + 30 210 8930 Sverige Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1Latvija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1United Kingdom (Northern Ireland) Gilead Sciences Ireland UC Tel: + 44 (0) 8000 113This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-702c9d84bc860bda988d99979df3de81
Resource Composition:
Generated Narrative: Composition composition-en-702c9d84bc860bda988d99979df3de81
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/14/938/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - zydelig
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp702c9d84bc860bda988d99979df3de81
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp702c9d84bc860bda988d99979df3de81
identifier:
http://ema.europa.eu/identifier
/EU/1/14/938/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Zydelig 100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en